| URL | https://www.thepharmaletter.com/article/wuxi-biolo |
| Source | ThePharmaLetter |
| Date Published | 06/11/2018 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | WuXi Biologics |
| Parent company | WuXi Pharma Tech |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 150 |
| Capital investment ($): | 60 |
| Country(ies) from which reshored: | Hong Kong |
| City reshored to: | Worchester |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biopharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Customer responsiveness improvement, Eco-system synergies, Government Incentives, Higher productivity, Infrastructure, Lead time/Time to market, Proximity to customers/market, Skilled workforce availability/training |